Validation & Impact

The preclinical research gap.

The future of drug discovery depends on predictive, reproducible, animal-free assay models that fit real industrial workflows.

REVOLV addresses this gap by bringing together three elements that are rarely aligned in 3D tissue model production: speed, biological relevance and workflow compatibility.

feature comparison

The REVOLV advantage

‎


Traditional bioprinting & 3D cultures

Traditional bioprinting & 3D cultures

The REVOLV standard

The REVOLV standard

Production speed

Minutes to hours per model; high cell starvation risk.

Minutes to hours per model; high cell starvation risk.

Seconds per construct; maximized cell viability.

Seconds per construct; maximized cell viability.

Structural integrity

Layer-by-layer printing can introduce mechanical stress and variability.

Layer-by-layer printing can introduce mechanical stress and variability.

Light-based volumetric printing forms the structure all at once.

Light-based volumetric printing forms the structure all at once.

Material origin

Frequently reliant on animal-derived matrices.

Frequently reliant on animal-derived matrices.

Animal-free, human-relevant bioresins.

Animal-free, human-relevant bioresins.

Automation flow

Manual handling or specialized custom plates required.

Manual handling or specialized custom plates required.

Designed for standard microplate compatibility, without custom hardware.

Designed for standard microplate compatibility, without custom hardware.

Quality

Batch-to-batch variation can limit reliability.

Batch-to-batch variation can limit reliability.

AI-guided calibration supports more consistent production.

AI-guided calibration supports more consistent production.

The liver validation case

The liver is a demanding target—dense, metabolically active, and dependent on flow. REVOLV validates the platform on a complex, perfusable, liver-relevant construct—designed for drug screening and toxicity testing.

Functional readouts such as detoxification activity, cell viability and liver-specific marker expression help translate the printed structure into pharma-relevant evidence, benchmarked against reference compounds used in drug-safety testing.

This builds on validated foundations — ENLIGHT’s proven hardware and UMC Utrecht's prior liver-organoid research

Bernal et al., Volumetric Bioprinting of Organoids and Optically Tuned Hydrogels to Build Liver-Like Metabolic Biofactories, Advanced Materials (2022).

Technical Enquiry

Printed rapidly.

Cultured intelligently.

Validated functionally.

Built for translation.

REVOLV’s value isn’t speed alone—it’s the consistency, automated format, and GMP-aligned quality logic pharmaceutical adoption requires.

Request a strategic briefing

REVOLV homepage

Reliable animal-free and high-throughput volumetric bioprinting of functional 3D assayS

Building on Horizon Europe / ENLIGHT

European Innovation Council: Funded by the European Union

Funded by the European Union under Grant Agreement 101286165. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.